Liposomal drug delivery system for lung diseases: Recent advancement and future perspectives

Affiliations

¹ Department of Pharmacy, Manmohan Memorial Institute of Health Sciences, Tribhuvan University, Kathmandu 44600, Nepal.
² College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea.
³ Department of Pharmacy, National Model College for Advanced Learning, Tribhuvan University, Lainchour, Kathmandu 44600, Nepal.
⁴ Industrial Pharmacy, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, 11439, USA.
⁵ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales 2007, Australia.
⁶ Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia.
⁷ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales 2007, Australia; Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia.
⁸ Medical Laboratory Technology Department, Faculty of Applied Health Sciences Technology, Pharos University in Alexandria, Canal El Mahmoudia Street, Beside Green Plaza Complex, 21648, Alexandria, Egypt.
⁹ Basic Sciences Department, Faculty of Computer Science and Artificial Intelligence, Pharos University in Alexandria, Canal El Mahmoudia Street, Beside Green Plaza Complex, 21648 Alexandria, Egypt.
¹⁰ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales 2007, Australia; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, New South Wales 2007, Australia; Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia.
¹¹ Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia; Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia; Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India; NICM Health Research Institute, Western Sydney University, Westmead, NSW 2145, Australia. Electronic address: Keshavraj.paudel@uts.edu.au.

PMID: 40886905
DOI: 10.1016/j.nano.2025.102855

Free article

Review

Liposomal drug delivery system for lung diseases: Recent advancement and future perspectives

Saroj Bashyal et al. Nanomedicine. 2025.

Free article

. 2025 Aug 29:69:102855.

doi: 10.1016/j.nano.2025.102855. Online ahead of print.

Authors

Affiliations

¹ Department of Pharmacy, Manmohan Memorial Institute of Health Sciences, Tribhuvan University, Kathmandu 44600, Nepal.
² College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea.
³ Department of Pharmacy, National Model College for Advanced Learning, Tribhuvan University, Lainchour, Kathmandu 44600, Nepal.
⁴ Industrial Pharmacy, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, 11439, USA.
⁵ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales 2007, Australia.
⁶ Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia.
⁷ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales 2007, Australia; Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia.
⁸ Medical Laboratory Technology Department, Faculty of Applied Health Sciences Technology, Pharos University in Alexandria, Canal El Mahmoudia Street, Beside Green Plaza Complex, 21648, Alexandria, Egypt.
⁹ Basic Sciences Department, Faculty of Computer Science and Artificial Intelligence, Pharos University in Alexandria, Canal El Mahmoudia Street, Beside Green Plaza Complex, 21648 Alexandria, Egypt.
¹⁰ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales 2007, Australia; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, New South Wales 2007, Australia; Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia.
¹¹ Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia; Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia; Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India; NICM Health Research Institute, Western Sydney University, Westmead, NSW 2145, Australia. Electronic address: Keshavraj.paudel@uts.edu.au.

PMID: 40886905
DOI: 10.1016/j.nano.2025.102855

Abstract

Lung diseases such as asthma, chronic respiratory diseases, and lung cancer are among the most prevalent and vulnerable health conditions. Various therapeutic approaches, including nucleic acids, peptides, and small molecules have been developed along with different delivery strategies for their treatment. Liposomes have been recognized as promising delivery candidates attributed to their biocompatibility, biodegradability, and ability to encapsulate both hydrophilic and hydrophobic drugs effectively. Their composition closely resembles pulmonary surfactants and can facilitate targeting deep lung tissue while also allowing localized drug delivery with less systemic exposure. The most rigorously explored route for delivering liposomal formulations to the lungs is inhalation. Additionally, liposomes help combat antimicrobial resistance and enhance targeted drug delivery by utilizing stimuli-responsive liposomes or modifying their physicochemical properties. Herein, we explore the liposomal delivery of different classes of drugs, their therapeutic potential in the treatment of lung disease, and discuss perspectives on clinical translation.

Keywords: Asthma; Drug delivery; Emphysema; Liposomes; Lung Cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest All authors declare no conflict of interest.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Liposomal drug delivery system for lung diseases: Recent advancement and future perspectives

Affiliations

Liposomal drug delivery system for lung diseases: Recent advancement and future perspectives

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

LinkOut - more resources

Full Text Sources